secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001193125-23-146576
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio preclinical data shows DeltEx gamma-delta T cells kill ovarian cancer cells, including resistant lines
--------------------------------------------------------------------------------

- Data presented at ASGCT 2023 demonstrate DeltEx T cells target and kill ovarian cancer cells even in platinum-resistant lines.
- Temozolomide (TMZ) combined with PARP inhibitors synergistically increased NKG2D-L expression, enhancing tumor cell visibility to gamma-delta T cells.
- CEO William Ho highlighted synergy of gamma-delta T cells with chemotherapy for solid tumors beyond the brain.
- CSO Lawrence Lamb noted potential for INB-400 in ovarian cancer and other solid tumors; further evaluation planned.
- Preclinical proof-of-concept supports DeltEx Drug Resistance Immunotherapy (DeltEx DRI) platform in challenging indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/0001193125-23-146576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523146576/d477840d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-146576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer